Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website: https://business.uoregon.edu/centers/lce

Clinical Trials

Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

Phase 3

Completed

Conditions: Chronic Pain

Interventions: Drug: Placebo
Drug: Ketamine

First Posted Date: 2016-09-30

Last Posted Date: 2021-04-15

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 106

Registration Number: NCT02920528

Locations: 🇺🇸
Emergency Department, Harbor-UCLA Medical Center, Torrance, California, United States

MyoVista Measurements in Patients With Atherosclerosis and CAD

Completed

Conditions: Atherosclerosis
Coronary Artery Disease (CAD)

First Posted Date: 2016-08-19

Last Posted Date: 2024-10-14

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 200

Registration Number: NCT02873052

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Stiolto Respimat
Drug: Placebo Respimat

First Posted Date: 2016-07-27

Last Posted Date: 2020-08-06

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 14

Registration Number: NCT02845752

Locations: 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States

Effective Approaches & Strategies to Ease Off Nasal CPAP In Preterm Infants

Not Applicable

Completed

Conditions: BronchoPulmonary Dysplasia
Neonatal Respiratory Distress Syndrome
Extremely Low Birth Weight Infant (ELBW)

First Posted Date: 2016-06-30

Last Posted Date: 2021-12-10

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT02819050

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

Phase 3

Conditions: Migraine Disorders

Interventions: Drug: Prochlorperazine

First Posted Date: 2016-05-23

Last Posted Date: 2018-01-05

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 80

Registration Number: NCT02779959

Locations: 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis

Not Applicable

Not yet recruiting

Conditions: Arthritis, Rheumatoid

First Posted Date: 2016-03-28

Last Posted Date: 2024-10-09

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 150

Registration Number: NCT02720874

Locations: 🇺🇸
The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States

ACTIMMUNE in Intermediate Osteopetrosis

Phase 2

Completed

Conditions: Osteopetrosis

Interventions: Drug: Interferon gamma-1b

First Posted Date: 2016-01-28

Last Posted Date: 2024-10-22

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 5

Registration Number: NCT02666768

Locations: 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization

Phase 2

Completed

Conditions: S. Aureus Oropharyngeal Colonization

Interventions: Drug: Saline Placebo
Drug: Chlorhexidine gluconate

First Posted Date: 2015-10-28

Last Posted Date: 2020-12-29

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 67

Registration Number: NCT02589067

Locations: 🇺🇸
Los Angeles BioMedical Research Institute (LA BioMed), Torrance, California, United States

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Phase 1

Completed

Conditions: Mucopolysaccharidosis Type VI
Mucopolysaccharidosis Type I
Mucopolysaccharidosis Type II

Interventions: Drug: Adalimumab
Other: Placebo

First Posted Date: 2015-05-07

Last Posted Date: 2017-09-15

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 2

Registration Number: NCT02437253

Locations: 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States

Safety of Nitroglycerin for Field Treatment of STEMI

Completed

Conditions: Myocardial Infarction

First Posted Date: 2015-04-02

Last Posted Date: 2017-08-25

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 940

Registration Number: NCT02407002

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy